Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. - Wikidata - awgldk - TriplyDB

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

http://www.wikidata.org/entity/Q38994189

about

Targeting molecular resistance in castration-resistant prostate cancer ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.SEOM clinical guidelines for the treatment of metastatic prostate cancer Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone.Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.Drug therapies for metastatic castration-resistant prostate cancer.What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?Prospects of estrogen receptor β activation in the treatment of castration-resistant prostate cancer.Role of taxanes in advanced prostate cancer.Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.Sequencing Treatment for Castration-Resistant Prostate Cancer.Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.Contemporary agents in the management of metastatic castration-resistant prostate cancer.Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis.Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer.Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations.The evolution of chemotherapy for the treatment of prostate cancer.Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.Combination of Carmustine and Selenite Inhibits EGFR Mediated Growth Signaling in Androgen-Independent Prostate Cancer Cells.Current treatment strategies for advanced prostate cancer.Aberrant TGF-β Signaling Drives Castration-Resistant Prostate Cancer in a Male Mouse Model of Prostate Tumorigenesis.The prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel.Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel.HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutami Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants

P2860

Q26795445-0F29554F-6D3F-4A2F-83FA-E929B1AE8289 Q26796568-39724AE4-D742-49A5-A44D-50AEA5C33652 Q26796704-66EAD6E9-5CFC-465A-986A-78A6F9250F78 Q28075965-97D318E3-8721-4B96-959B-2DF36B43A116 Q30244818-D896A08E-4971-4F01-B77F-29E5E6BE953E Q33440646-DBFB6331-F688-4935-925B-D7AA8ECA0EE8 Q34553405-0A03EBF5-6F08-4FC7-813F-CB9262E02D6D Q36586089-C33E1044-22A4-4BA7-849F-D1E1A283D4BA Q36823062-40320477-1A1D-411D-9C86-7287C616B26E Q37726362-FACCA103-B321-4891-8FF8-D97699DA91F5 Q37735587-F58576A0-CBCF-42FE-B972-8BB822DF6252 Q38566800-E80770BF-1D95-4B99-BA5F-28E086AF39E5 Q38587547-7F7C85E0-EA13-4B26-8728-C06A7F553A48 Q38708804-222CF824-EF84-4D35-81D5-3F77B9017631 Q38726366-A02C1F88-3E99-4795-A632-FD8073BE67DE Q38769775-B31801E6-FF5C-4B9D-A629-7009AD678FD0 Q39002328-F0C87FFB-3A30-4E05-B791-67F3C771AA3E Q39016544-9EE4DE1F-05F7-481C-AF9E-8AB3B54B78EA Q39092924-B66DF7C4-1B45-4723-AE47-8CA1CEECAF2B Q39172440-520EC5E8-BC99-41D2-A51A-A5FE76668672 Q39205202-C826DA67-7872-4FAD-90BC-D25D38F10239 Q39612278-B11954A8-D8A2-4258-8255-05BB6CB2263D Q41484469-95650022-6254-4AE4-AF92-493E35A95806 Q45943517-AC01DABA-8E87-49B0-BB73-4B52CDE8BE3D Q46131083-425C2A40-FE32-435E-BE19-2CCFFFA949E8 Q46495734-E6FE7753-DC5C-46F1-B562-A41F28244503 Q47293703-67CD0728-FE02-4948-A0C7-244EFE9D63F2 Q48107095-3AA41E37-733A-4BCB-B699-60DF0E038162 Q48110667-F6C2BE36-3770-49C2-B2D2-55DD5896AD28 Q48248291-189A6E1C-BA69-4E3E-BD5C-33FDB6E68D0C Q48561494-2DC17380-7842-4D41-9E9B-04839D591F67 Q51092129-A1D279C2-D44B-4898-8008-91171FCCAAEB Q51746022-EF97A1BB-61BC-4924-81F7-62A852B275E9 Q53735518-E2A75FE1-B415-4460-9446-F0DC8B040709 Q53737270-CD2BA12D-81CC-4744-9721-9938588BF787 Q53822455-A405EDA1-B247-47D1-9831-CF68BE07C760 Q55004240-965D142C-49BE-48D0-A1CC-46F2A631462C Q58697074-C1C9A3CB-D2FB-4238-9B56-D0DA00797FBF

P2860

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

http://www.wikidata.org/entity/Q38994189

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Cabazitaxel Remains Active in ...... or Pathway Targeted Therapies.

@en

type

label

Cabazitaxel Remains Active in ...... or Pathway Targeted Therapies.

@en

prefLabel

Cabazitaxel Remains Active in ...... or Pathway Targeted Therapies.

@en

P1433

Q38994189-01CF7C76-B6C9-4EDD-99D9-2471C30F03B3

P1476

Q38994189-C5675F64-EC56-4CB6-98DB-FB4E684259B4

P2093

Q38994189-152618CD-D6C6-4EA7-BA3E-B4FEBB8F38ED

Q38994189-24528CCB-7065-4873-9E53-D40B6D250EBE

Q38994189-31491498-4A14-4772-A482-DA715724A41E

Q38994189-44B9E58C-4732-4059-B619-D4BA57F24122

Q38994189-698E3A5D-FF7B-4236-B942-074C9028BCC5

Q38994189-9155B0B5-3BDB-4B53-8A02-797D0B685B3C

Q38994189-98CE7411-F947-42BB-8BC7-848562999D05

Q38994189-A9F0DB90-4AFE-4730-A9C6-8E8BE9B43F3E

Q38994189-BA6F6B62-645E-4D98-A600-617D8E54DC64

Q38994189-C00BDABD-5621-49BE-AC3C-496E837E79AD

P304

Q38994189-CC53B065-4DFC-40E3-8480-5DA4A747902C

P31

Q38994189-847D236D-2795-49D8-9A18-6510A762923A

P356

Q38994189-6848B1D9-05D1-4F77-AB54-D16959C4E073

P407

Q38994189-8C47237B-35B7-476D-9689-EF8965D8A25A

P433

Q38994189-3E65AEF1-C2CC-4BD5-8D8E-B83C42ECF47E

P478

Q38994189-845ECFDE-D45A-43C0-B28A-3B89F0FF248B

P50

Q38994189-DBD7AEE9-B545-4E7B-90DC-3631C0C09BAE

P577

Q38994189-D5A28858-042F-4961-B92F-85BE000254F6

P698

Q38994189-553B1415-6F90-4C29-AED7-BED3DD4D634E

P356

J.EURURO.2014.04.015

P1433

European Urology

P1476

Cabazitaxel Remains Active in ...... or Pathway Targeted Therapies.

@en

P2093

Aline Guillot

http://www.w3.org/2001/XMLSchema#string

Chris Wang

http://www.w3.org/2001/XMLSchema#string

Christophe Massard

http://www.w3.org/2001/XMLSchema#string

Dorota Gajda

http://www.w3.org/2001/XMLSchema#string

Laurence Albigès

http://www.w3.org/2001/XMLSchema#string

Marine Gross-Goupil

http://www.w3.org/2001/XMLSchema#string

Martin Gleave

http://www.w3.org/2001/XMLSchema#string

Nader Al Nakouzi

http://www.w3.org/2001/XMLSchema#string

Philippe Beuzeboc

http://www.w3.org/2001/XMLSchema#string

Sylvestre Le Moulec

http://www.w3.org/2001/XMLSchema#string

P304

228-235

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2014.04.015

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24837187

http://www.w3.org/2001/XMLSchema#string